Ashley Douthitt

Ms. Ashley Douthitt

Texas A&M Health Science Center, College Station, Texas, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
AGAnna Galkin
Anna Galkin
RSRavikumar Sitapara
Ravikumar Sitapara
BCBryan Clemons
Bryan Clemons
EGEduardo Garcia
Eduardo Garcia
MKMichael Kennedy
Michael Kennedy
LZLawrence S. Zisman
Lawrence S. Zisman
Background Signaling through platelet-derived growth factor receptor (PDGFR), colony stimulating factor 1 receptor (CSF1R), and c-KIT plays a critical role in pulmonary arterial hypertension (PAH). We examined the preclinical efficacy of inhaled seralutinib, a unique small molecule PDGFR/CSF1R/c-KIT kinase inhibitor in clinical development for PAH, in comparison to a proof-of-concept kinase inhibitor, imatinib. Methods Seralutinib and imatinib potency and selectivity were compared. Inhaled seralutinib pharmacokinetics/pharmacodynamics were studied in healthy rats. Efficacy was evaluated in two rat models of PAH: SU5416/Hypoxia (SU5416/H) and monocrotaline pneumonectomy (MCTPN). Effects on inflammatory/cytokine signaling were examined. PDGFR, CSF1R, and c-KIT immunohistochemistry (IHC) in rat and human PAH lung samples and miRNA analysis in the SU5416/H model were performed. Results Seralutinib potently inhibited PDGFRα/β, c-KIT and CSF1R. Inhaled seralutinib demonstrated dose-dependent inhibition of lung PDGFR and c-KIT signaling, and increased bone morphogenetic protein receptor type 2 (BMPR2). Seralutinib improved cardiopulmonary hemodynamics and reduced small pulmonary artery muscularisation and right ventricle hypertrophy in both models. In the SU5416/H model, seralutinib improved cardiopulmonary hemodynamics, restored lung BMPR2 protein levels, and decreased n-terminal prohormone of brain natriuretic peptide (NT-proBNP) more than imatinib. Quantitative IHC in human lung PAH samples demonstrated increased PDGFR, CSF1R, and c-KIT. miRNA analysis revealed candidates that could mediate seralutinib effects on BMPR2. Conclusions Inhaled seralutinib was an effective treatment of severe PAH in two animal models, with improved cardiopulmonary hemodynamics, reduction in NT-proBNP, reverse remodeling of pulmonary vascular pathology, and improvement in inflammatory biomarkers. Seralutinib showed greater efficacy compared to imatinib in a preclinical study.

24 March 2022 in Biology
Verified
Journal Article
Open access
PDF file
AGAdel Ghnenis
Adel Ghnenis
Calvin Larry JonesCalvin Larry Jones
Calvin Larry Jones
ASArthur Sefiani
Arthur Sefiani
Ashley DouthittAshley Douthitt
Ashley Douthitt
ARAndrea J. Reyna
Andrea J. Reyna
Cédric GeoffroyCédric Geoffroy
Cédric Geoffroy
Changes in cardiometabolic functions contribute to increased morbidity and mortality after chronic spinal cord injury. Despite many advancements in discovering SCI-induced pathologies, the cardiometabolic risks and divergences in severity-related responses have yet to be elucidated. Here, we examined the effects of SCI severity on functional recovery and cardiometabolic functions following moderate (50 kdyn) and severe (75 kdyn) contusions in the thoracic-8 (T8) vertebrae in mice using imaging, morphometric, and molecular analyses. Both severities reduced hindlimbs motor functions, body weight (g), and total body fat (%) at all-time points up to 20 weeks post-injury (PI), while only severe SCI reduced the total body lean (%). Severe SCI increased liver echogenicity starting from 12 weeks PI, with an increase in liver fibrosis in both moderate and severe SCI. Severe SCI mice showed a significant reduction in left ventricular internal diameters and LV volume at 20 weeks PI, associated with increased LV ejection fraction as well as cardiac fibrosis. These cardiometabolic dysfunctions were accompanied by changes in the inflammation profile, varying with the severity of the injury, but not in the lipid profile nor cardiac or hepatic tyrosine hydroxylase innervation changes, suggesting that systemic inflammation may be involved in these SCI-induced health complications.

10 January 2026 in Journal of Neurotrauma
Verified
Journal Article
Open access
TSTheresa C. Sutherland
Theresa C. Sutherland
SLSighild Lemarchant
Sighild Lemarchant
Ashley DouthittAshley Douthitt
Ashley Douthitt
ALAlexandra H. Lopez
Alexandra H. Lopez
LKLily Kuhlman
Lily Kuhlman
Cédric GeoffroyCédric Geoffroy
Cédric Geoffroy
Spinal cord injury (SCI) represents a major public health issue, as the consequences are often irreversible with no treatment currently available. This results in a growing population living with long-lasting motor, sensory, and/or autonomic impairments directly related to their SCI. Here, we have evaluated the therapeutic potential of a thrombospondin repeats peptide analogue, named NX210, in a mouse hemisection model of SCI. Adult female mice were subjected to a thoracic level 8 dorsal hemisection, and treated with intraperitoneal injections of NX210 starting at 4 h post-injury and then twice a week at 4, 8, or 16 mg/kg. Hind limb motor function was assessed once a week for 10 weeks post-injury using the Basso Mouse Scale (BMS) score and sub-score, the rotarod, and the activity chamber tests. Mice were then sacrificed, and the spinal cords were collected for immunohistochemistry. Interestingly, NX210 improved functional recovery (BMS score and sub-score, latency to fall from the rotarod, spontaneous locomotor activity) with rapid rises in function that were maintained throughout the 10-week study. This was accompanied by a reduction of nociceptive reactivity assessed by the tail flick test. NX210 treatment also increased myelin basic protein and reduced neuron/glial antigen 2 at the injury site 10 weeks post-injury while no significant effects were observed on lesion size, inflammation, and neuron survival. Overall, this study highlights a potential new therapeutic strategy to promote repair and decrease long-lasting functional impairments after SCI.